ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma

Wang, Yonggang; Wang, Chang; Zhang, Yanqiao; Hao, Jiqing; Yang, Nong; Wang, Jvfeng; Peng, Min; Liu, Tianshu; Zhang, Guifang; Zhan, Xianbao; Zeng, Shan; Zhang, Yifan; Gao, Yong*; Yao, Yang*复旦大学; 安徽医科大学; 吉林大学; 上海交通大学; 哈尔滨医科大学; 郑州大学; 同济大学; 武汉大学; 中国科学院; 6; 1; y
Frontiers in Oncology2022-10-18DOI: 10.3389/fonc.2022.876899
1被引8阅读
引用收藏
分享

摘要

Background and purposeThe objective of this study was to investigate the pharmacokinetics, safety, and antitumor activity of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and evaluate the effect of dose titration on dosage optimization for individual patients. MethodsPatient with advanced gastric adenocarcinoma progressed after at least one line of chemotherapy were enrolled. Apatinib was given orally once daily starting at 500 mg for 14 days, then up-titrated to 750 mg for 14 days, and then proceeded to a maximum dose of 850 mg. Dose up-titration determination was based on toxicity. The 28-day treatment cycles continued until disease progression, intolerable toxicities, withdrawal of consent, or investigator' decision. ResultsA total of 60 patients were enrolled, with 17, 18, and 25 patients receiving a maximum dose of 500 mg, 750 mg, and 850 mg, respectively. The pharmacokinetic parameters varied considerably, with the interpatient coefficient of variation for steady state areas under the plasma concentration time curve (AUC(ss)) and the mean maximum concentration of both > 50%. During 500 mg and 750 mg dosing stage, drug exposures in patients with a maximum dosage of 850 mg were lower than in those not titrated to 850 mg. Patients with total gastrectomy exhibited significantly lower AUC(ss) than patients with partial or no gastrectomy (p = 0.004 and 0.032, respectively). Toxicities were tolerable, and disease control rate was 39.5% (95% CI 25.0%-55.6%). ConclusionsApatinib dose titration based on toxicity could be used in clinical practice to provide optimal dosage for individual patients.

学科与关键词

关键词
apatinibangiogenesisgastric adenocarcinomapharmacokineticsVEGFRVEGFR-2
相关
加载中…
  • Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
    Li, Jin; Qin, Shukui*; Wen, Lu; Wang, Junsheng; Deng, Wenying; Guo, Weijian; Jia, Tongfu; Jiang, Da; Zhang, Guifang; He, Yifu; Ba, Yi; Zhong, Haijun; Wang, Lin; Lin, Xiaoyan; Yang, Jianwei; Zhao, Jun; Bai, Yuxian; Wu, Xiangyuan; Gao, Feng; Sun, Guogui; Wu, Yongjuan; Ye, Feng; Wang, Qiong; Xie, Zhong; Yi, Tienan; Huang, Yong; Yu, Guohua; Lu, Lin; Yuan, Ying; Li, Wei; Liu, Likun; Sun, Yuping; Sun, Ying; Yin, Lifeng; Hou, ZhiguoBMC Medicine, 2023, 21(1): 173.被引 1
  • Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
    Qu, Jinglei; He, Xin; Luo, Ying; Yu, Ping; Chen, Ying; Liu, Jing; Wang, Xin; Wang, Chang; Liang, Tingting; Bai, Yuxian; Han, Yu; Man, Li; Leng, Chuanchun; Zhou, Caiyun; He, Lijie; Liu, Yunpeng*; Qu, Xiujuan*Frontiers in Oncology, 2023, 13: 1072943.
  • The Effects of Drug Exposure and Single Nucleotide Polymorphisms on Aaptinib-Induced Severe Toxicities in Solid Tumors
    Chen, Youhao; Lin, Yaobin; Guan, Shaoxing; Zhao, Zerui; Lin, Daren; Guan, Jin; Zhou, Chengzhi; Liu, Junling; Cao, Xiaolong; Lin, Zhichao; Chen, Diyao; Shang, Jianbiao; Zhang, Weijian; Chen, Huohui; Chen, Likun; Ma, Shudong; Gu, Lijia; Zhao, Jian; Huang, Min*; Wang, Xueding*; Long, Hao*Drug Metabolism and Disposition, 2023, 51(12): 1583-1590.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-10-18
卷期
第 12 卷
页码
876899
DOI
10.3389/fonc.2022.876899
期刊等级
3区
成果收录
SCIE

作者

  • W

    Wang, Yonggang (第一作者)

    6 · shanghai jiao tong univ

  • W

    Wang, Chang

    jilin univ

查看全部 14 位作者收起作者
  • Z

    Zhang, Yanqiao

    harbin med univ

  • H

    Hao, Jiqing

    1 · anhui med univ

  • Y

    Yang, Nong

    hunan canc hosp

  • W

    Wang, Jvfeng

    zhengzhou univ

  • P

    Peng, Min

    wuhan univ

  • L

    Liu, Tianshu

    fudan univ

  • Z

    Zhang, Guifang

  • Z

    Zhan, Xianbao

    second mil med univ

  • Z

    Zeng, Shan

  • Z

    Zhang, Yifan

    chinese acad sci · shanghai inst mat med

  • G

    Gao, Yong (通讯)

    tongji univ

  • Y

    Yao, Yang (通讯)

    6 · shanghai jiao tong univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417